Impact of Persistent Multidrug-Resistant Gram-Negative Bacteremia on Clinical Outcome and Mortality.

Shiori Kitaya, Hajime Kanamori, Yukio Katori, Koichi Tokuda
Author Information
  1. Shiori Kitaya: Department of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
  2. Hajime Kanamori: Department of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan. ORCID
  3. Yukio Katori: Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan.
  4. Koichi Tokuda: Department of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan. ORCID

Abstract

The clinical aspects of persistent bacteremia (PB) caused by gram-negative rods (GNRs) in terms of antimicrobial resistance (AMR) and PB clearance status are unclear. This secondary analysis of a retrospective cohort study investigated differences in PB caused by Enterobacterales and glucose non-fermentative GNRs (NF-GNRs) based on AMR and PB clearance. We retrospectively surveyed medical records at Tohoku University Hospital. Patients for whom blood cultures were performed between January 2012 and December 2021 were recruited. PB cases were grouped based on AMR and PB clearance; the characteristics of PB due to each bacterial pathogen were examined. The main outcome variable was mortality. The late (30-90-day) mortality rate was significantly higher in the multidrug-resistant (MDR) group than in the non-MDR group for Enterobacterales. However, no significant difference was noted in mortality rates between NF-GNRs with and without AMR. Mortality rates tended to be higher in the non-PB-clearance group than in the clearance group for both Enterobacterales and NF-GNRs. Since the mortality rate was higher in the MDR group in the case of Enterobacterales PB, more careful management is necessary for this condition. Follow-up blood cultures and confirming the clearance of PB are useful for improving the survival rate.

Keywords

References

  1. J Cancer Res Ther. 2013 Apr-Jun;9(2):267-71 [PMID: 23771371]
  2. Open Forum Infect Dis. 2020 Mar 28;7(4):ofaa110 [PMID: 32328509]
  3. Microb Drug Resist. 2016 Jul;22(5):412-31 [PMID: 26866778]
  4. MMWR Morb Mortal Wkly Rep. 2013 Mar 8;62(9):165-70 [PMID: 23466435]
  5. PLoS One. 2018 Jun 28;13(6):e0199531 [PMID: 29953464]
  6. J Cardiothorac Vasc Anesth. 2015 Feb;29(1):59-63 [PMID: 25169897]
  7. Clin Infect Dis. 2019 Feb 15;68(5):873-884 [PMID: 30475989]
  8. Minerva Anestesiol. 2020 May;86(5):498-506 [PMID: 32100514]
  9. Clin Microbiol Infect. 2020 Jul;26(7):904-910 [PMID: 32114010]
  10. BMC Infect Dis. 2021 Jul 2;21(1):636 [PMID: 34215207]
  11. Future Microbiol. 2020 Nov 3;:1489-1505 [PMID: 33140656]
  12. Cancer. 2006 May 15;106(10):2258-66 [PMID: 16575919]
  13. Antibiotics (Basel). 2020 Sep 22;9(9): [PMID: 32971809]
  14. J Microbiol Immunol Infect. 2010 Jun;43(3):233-9 [PMID: 21291852]
  15. Curr Opin Infect Dis. 2022 Dec 1;35(6):583-588 [PMID: 35852791]
  16. Pathogens. 2023 Jan 29;12(2): [PMID: 36839484]
  17. J Antimicrob Chemother. 2011 Mar;66(3):657-63 [PMID: 21193475]
  18. Infect Dis Health. 2019 Nov;24(4):222-228 [PMID: 31401054]
  19. Clin Microbiol Infect. 2012 Mar;18(3):268-81 [PMID: 21793988]
  20. J Vasc Access. 2022 Mar;23(2):328-329 [PMID: 33499702]
  21. Curr Pharm Des. 2013;19(2):223-38 [PMID: 22894617]
  22. Antimicrob Agents Chemother. 2008 Mar;52(3):813-21 [PMID: 18070961]
  23. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4910-9 [PMID: 27270289]
  24. BMC Infect Dis. 2016 Jun 13;16:286 [PMID: 27296858]
  25. Front Med (Lausanne). 2019 Apr 16;6:74 [PMID: 31041313]
  26. Br J Community Nurs. 2018 Aug 2;23(8):382-387 [PMID: 30063389]
  27. Antimicrob Agents Chemother. 2009 Mar;53(3):1074-9 [PMID: 19075047]
  28. Zhonghua Yi Xue Za Zhi. 2014 Mar 11;94(9):684-7 [PMID: 24842209]
  29. Arch Med Res. 2021 Nov;52(8):817-827 [PMID: 34583850]
  30. Clin Infect Dis. 2011 Jul 1;53(1):60-7 [PMID: 21653305]
  31. Ann Oncol. 2016 Oct;27(10):1916-22 [PMID: 27456299]
  32. Infection. 2022 Jun;50(3):689-697 [PMID: 35060101]

Grants

  1. unknown/MIURA CO.,LTD

Word Cloud

Created with Highcharts 10.0.0PBclearanceEnterobacteralesgroupAMRmortalitypersistentbacteremiaNF-GNRsbloodratehighercausedgram-negativeGNRsantimicrobialresistancebasedculturesMDRratesMortalityclinicalaspectsrodstermsstatusunclearsecondaryanalysisretrospectivecohortstudyinvestigateddifferencesglucosenon-fermentativeretrospectivelysurveyedmedicalrecordsTohokuUniversityHospitalPatientsperformedJanuary2012December2021recruitedcasesgroupedcharacteristicsduebacterialpathogenexaminedmainoutcomevariablelate30-90-daysignificantlymultidrug-resistantnon-MDRHoweversignificantdifferencenotedwithouttendednon-PB-clearanceSincecasecarefulmanagementnecessaryconditionFollow-upconfirmingusefulimprovingsurvivalImpactPersistentMultidrug-ResistantGram-NegativeBacteremiaClinicalOutcomefollow-upcultureglucose-nonfermentingrod

Similar Articles

Cited By